Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.
The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.
Pressure is building on IP owners to offer up access to technology that could help fight COVID-19. Rory O'Neill looks at some of the implications for the patent system.
Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.
Richard Fawcett, senior associate at Powell Gilbert, outlines why the UK patent system poses no obstacle to the UK government’s rallying call for ventilator production amid the COVID-19 pandemic.
One of the perennial inherent challenges for legislators and regulators is crafting laws and regulatory frameworks that are firm enough to deal with the issues of the present, but flexible enough to cater for the challenges of the future, as Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.